Bertis Selected as a First Penguin-type Start-Up Business
by the Korea Credit Guarantee Fund
- Recognition of Bertis’ competitiveness, including its entrepreneurship, creativity, technology and potential for growth
Considered as a leading company that guides a core growth engine industry of the national economy
<(From left) Seung-man Han, CEO of Bertis, taking a commemorative photograph together
with Kim Dong-sin, branch manager of the East Seoul Start-Up branch of the Korea Credit Guarantee Fund,
after being selected as a First Penguin-type Start-up Business by the Korea Credit Guarantee Fund>
Bertis (CEO: Seung-man Han), a proteomics-based early diagnosis technology development company, announced on the 14th that they had been selected as a “First Penguin-type Start-up Business” by the Korea Credit Guarantee Fund.
Bertis is a company that has developed a multi-biomarker-based breast cancer early diagnosis technology called ‘MASTOCHECK’ that is a blood test method aimed at the public for easy screening of early-stage breast cancer. Three types of protein biomarkers in the blood that are related to breast cancer are measured quantitatively, and the values are run through a unique patented algorithm to diagnose early-stage breast cancer. Only one cc of blood can diagnose breast cancer at any stage. Stage 1, which is difficult to identify with other screening methods, can be diagnosed with a high accuracy rate of 92% (based on a domestic patent).1,2
'MASTOCHECK' acquired New Excellent Technology (NET) certification from the Korea Health Industry Development Institute because of its high potential of aiding diagnosis if an image is difficult to understand or decipher in early-stage breast cancer. Innovative medical technology, 'MASTOCHECK,' can positively impact the global market due to its simplicity and convenience. 3
Bertis will receive a total of 1.5 billion won in guaranteed support for three years, including 1 billion won this year.
“License from the Ministry of Food and Drug Safety and New Excellent Technology certification, and nomination as a First Penguin-type Start-up Business are an indication that our proteomics-based early-stage diagnostic technology, MASTOCHECK, is an innovative breast cancer solution. And I am very grateful for these recognitions from the public," said Seung-man Han, CEO of Bertis. He added, “Based on our First Penguin-type Start-up Business status, we will work actively to lead this core growth engine industry of the national economy”.
1) Ministry of Food and Drug Safety’s medical device e-petition site. MASTOCHECK product information (license no.: Heo 19-5). Accessed Oct 15, 2019 at https://emed.mfds.go.kr/#!CECAB01F020
2) Korean Intellectual Property Office. Patent registration 10-1431062: A breast cancer diagnostic kit containing a multibiomarker set for breast cancer diagnosis, its detection method and antibodies
3) Korea Health Industry Development Institute press release. The Korea Health Industry Development Institute hosted the 2019 2nd New Excellent Technology (NET) Certification Awards Ceremony. Accessed Oct 15, 2019 at https://www.khidi.or.kr/board/view?pageNum=1&rowCnt=10&no1=2128&linkId=48797272&menuId=MENU00100&maxIndex=00487972949998&minIndex=00487355949998&schType=0&schText=&schStartDate=&schEndDate=&boardStyle=&categoryId=&continent=&country=